Advanced searches left 3/3

Acute Promyelocytic Leukemia - DOAJ

Summarized by Plex Scholar
Last Updated: 04 October 2022

* If you want to update the article please login/register

Case Report: Successful therapy with all-trans retinoic acid combined with chemotherapy followed by hematopoietic stem cell transplantation for acute promyelocytic leukemia carrying the BCOR-RARA fusion gene

More than 80% of APL's have PML-RARA fusion, and less than 2% of APL's have other RARA gene partners, including variant APL. We reported a vAPL with BCOR-RARA in the third case of BCOR-RARA APL released in the paper. In addition, ATRA, chemotherapy, and allo-HSCT were all recommended as the best alternative for those vAPL patients who were at a high risk of relapse.

Source link: https://doi.org/10.3389/fonc.2022.1013046


Case report: A rare case of acute myeloid leukemia with CPSF6–RARG fusion resembling acute promyelocytic leukemia

They resemble classical acute promyelocytic leukemia patients in clinical appearance, morphology, and immunophenotype, but not have the promyelocytic leukemia fusion gene, according to the u2013RARA fusion gene. We found a case of AML resembling APL in clinical presentation and laboratory findings containing a rare cleavage and polyadenylation-specific gene in the RARG fusion gene.

Source link: https://doi.org/10.3389/fonc.2022.1011023


Predictors of early death and clinical features in newly diagnosed patients with low-intermediate risk acute promyelocytic leukemia

ConclusionsSixty patients with newly diagnosed low-risk acute promyelocyte leukemia in Mianyang Central Hospital from January 2013 to December 2021 were retrospectively reviewed, with the aim of determining the clinical characteristics and potential predictors of early death in newly diagnosed patients with acute promyelocyty leukemia with low-intermediate risk from January 2013 to December 2021. Many with intermediate-risk APL patients had elevated white blood cell counts, a higher risk of bone marrow promyelocytes, a greater number of platelet transfusions during therapy, and earlier deaths in patients with low risk APL. Conclusions: APL patients with high risk APL (APL) in patients with poor-intermediate risk APL, HGB 65g/L at diagnosis was an independent risk factor for early death.

Source link: https://doi.org/10.3389/fonc.2022.895777

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions